More than 50 million people worldwide are living with epilepsy, making it one of the most common neurological conditions on the planet. In the United States alone, roughly 3.4 million people have active epilepsy: about 2.9 million adults and 456,000 children aged 17 or younger, based on CDC estimates from 2021 and 2022.
Global Numbers and Where the Burden Falls
That 50 million figure, widely cited by the World Health Organization, isn’t evenly distributed. About 80% of people with epilepsy live in low- and middle-income countries, where infectious diseases, limited prenatal care, and birth-related complications all raise the risk. New diagnoses reflect this gap too: high-income countries see roughly 49 new cases per 100,000 people each year, while low- and middle-income countries can see rates nearly three times higher, up to 139 per 100,000.
Access to treatment is a major part of the problem. Three quarters of people with epilepsy in low-income countries do not receive the medication they need, even though basic seizure medications are inexpensive and widely available in wealthier nations. This treatment gap means millions of people experience uncontrolled seizures that could otherwise be managed.
Your Lifetime Risk of Developing Epilepsy
Epilepsy can begin at any age, and the cumulative odds are higher than most people expect. Research published in the journal Neurology found that the lifetime risk of developing epilepsy reaches about 1% by age 20, climbs to roughly 1.6% by age 50, and hits 3% by age 80. In other words, about 1 in 33 people will develop epilepsy at some point in their lives. The condition has two peak windows: early childhood and older adulthood, when strokes, brain injuries, and neurodegenerative conditions become more common triggers.
How Many People Become Seizure-Free
A diagnosis of epilepsy doesn’t necessarily mean a lifetime of seizures. About 6 out of 10 people become seizure-free within a few years of starting treatment. For many, the first medication tried does the job: 50 to 60% of people achieve seizure freedom with their initial prescription. A second medication helps an additional 11 to 20 out of every 100 people who didn’t respond to the first.
Children tend to fare especially well. Around 74 out of 100 children with new-onset seizures become seizure-free within two years, and more than half eventually outgrow epilepsy entirely. Only about 9 out of 100 children go on to develop uncontrolled epilepsy over the long term.
The long view is encouraging for most people. Twenty years after diagnosis, 75 out of 100 people will have been seizure-free for at least five years, though some still take daily medication to maintain that control. Still, at any given time, roughly 30 out of 100 people with epilepsy have seizures that aren’t fully controlled. For adults specifically, about 25 out of 100 will develop what’s considered uncontrolled epilepsy.
Mortality and Serious Risks
Most people with epilepsy live full, normal-length lives, but the condition does carry some serious risks. The most concerning is sudden unexpected death in epilepsy, known as SUDEP. This occurs at a rate of roughly 2.6 per 1,000 people with epilepsy per year, with higher risk among those whose seizures remain uncontrolled. SUDEP is believed to happen when a seizure disrupts breathing or heart rhythm during sleep. Consistent seizure control through medication is the most effective way to reduce this risk.
U.S. Numbers in Context
The 3.4 million Americans with active epilepsy represent about 1% of the population, a proportion consistent with prevalence rates in other high-income countries. “Active epilepsy” in these estimates means someone currently taking seizure medication, having had a seizure in the past year, or both. The total number of people who have ever been diagnosed with epilepsy is considerably higher, since many children outgrow it and some adults go into lasting remission.
To put 3.4 million in perspective, epilepsy affects more Americans than Parkinson’s disease, multiple sclerosis, and cerebral palsy combined. Despite those numbers, public awareness of the condition remains relatively low compared to other neurological disorders, and stigma continues to be a barrier for many people living with it worldwide.